BofA upgraded Rocket Pharmaceuticals (RCKT) to Buy from Neutral with a price target of $10, up from $4.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCKT:
- Citi says FDA may take ‘more comprehensive look’ at Sarepta Elevidys adjustment
- Target names CEO successor, Guess to go private: Morning Buzz
- Rocket alignment with FDA ‘sounds reasonable,’ says Chardan
- Cautious Optimism: Hold Rating on Rocket Pharmaceuticals Amid Resumed Phase II Study with Protocol Changes
- Morning Movers: Target sinks following Q2 earnings and CEO succession plan